Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Published 15/02/2024, 10:30
© Reuters Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

U.S. stock futures were higher this morning, with the Dow futures trading higher by around 70 points on Thursday.

Shares of Cisco Systems, Inc. (NASDAQ: CSCO) fell in today’s pre-market trading following second-quarter results.

Cisco reported better-than-expected second-quarter financial results but issued weak full-year 2024 guidance. The company also announced a restructuring plan to cut approximately 5% of its global workforce.

Cisco Systems shares fell 5.2% to $47.68 in pre-market trading.

Here are some big stocks recording losses in today’s pre-market trading session.

  • Nu Skin Enterprises, Inc. (NYSE: NUS) shares dipped 24% to $13.25 in pre-market trading after the company reported fourth-quarter financial results.
  • Fastly, Inc. (NYSE: FSLY) shares fell 23.1% to $18.10 in pre-market trading after the company reported mixed fourth-quarter financial results.
  • enGene Holdings Inc. (NASDAQ: ENGN) shares declined 13.3% to $14.30 in pre-market trading. enGene shares jumped around 116% on Wednesday after the company announced an oversubscribed $200 million private placement financing.
  • Herbalife Ltd. (NYSE: HLF) shares fell 12.3% to $10.30 in pre-market trading following weak quarterly earnings.
  • Twilio Inc. (NYSE: TWLO) fell 12.1% to $63.51 in pre-market trading after the company reported fourth-quarter financial results.
  • Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) tumbled 10.7% to $10.64 in pre-market trading after jumping around 70% on Wednesday.
  • Larimar Therapeutics, Inc. (NASDAQ: LRMR) fell 7.9% to $11.01 in pre-market trading after gaining over 36% on Wednesday. Larimar Therapeutics priced the public offering of 17.16 million shares at $8.74/share for gross proceeds of approximately $150 million.
  • Rollins, Inc. (NYSE: ROL) fell 6.3% to $41.48 in pre-market trading following quarterly results.
  • Albemarle Corporation (NYSE: ALB) shares fell 5.6% to $108.00 in pre-market trading following quarterly results.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Now Read This: Investor Sentiment Improves; Dow Jumps Over 150 Points

Don’t forget to check out our premarket coverage here

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.